logo-loader
viewOpen Orphan PLC

Open Orphan says Venn Life Sciences division lands major contract with a top global pharmaceutical company

Investors were told the agreement was the result of “earlier successful contracts between the companies”

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) revealed that its Venn Life Sciences division has won a “major contract” with a leading vaccine developer and one of the top pharmaceutical companies in the world.

While the full details of the deal weren’t provided, in a statement Open Orphan said Venn would help “obtain and support market access of newly developed vaccines into the EU and US markets until the end of 2020”.

Investors were told the agreement was the result of “earlier successful contracts between the companies”.

A delighted Cathal Friel, chairman of Open Orphan, said the contract reinforced the company’s position as one of the leading service providers to the vaccine industry globally.

“As a result of the (coronavirus) COVID-19 pandemic, the vaccine industry is now an increasingly important and rapidly growing sector with many large pharmaceutical companies now directing huge amounts of resources towards their vaccine divisions to progress both COVID-19 and non-COVID-19 vaccines,” he added.

“Open Orphan is ideally positioned to capitalise upon this trend as we build the Company into a growing, profitable pharmaceutical services business."

The company has been one of a handful of healthcare success stories during the coronavirus pandemic and lockdown. Its hViVO operation has launched a best-in-class coronavirus testing service and has a London quarantine clinic with an onsite virology lab that can be used by makers of COVID vaccines.

Quick facts: Open Orphan PLC

Price: 12.5 GBX

AIM:ORPH
Market: AIM
Market Cap: £82.98 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan PLC - Proactive One2One Virtual Event

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to investors at the Proactive One2One Virtual Event. Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

1 day, 7 hours ago

2 min read